Europeanhhm

QIAGEN Enhances QCI Interpret Software with Advanced AI Capabilities to Provide Comprehensive Clinical Exome Coverage

Friday, September 29, 2023

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has unveiled an expansion of its clinical decision-making software, QIAGEN Clinical Insight Interpret (QCI Interpret), which now incorporates advanced artificial intelligence (AI) capabilities to encompass a wide range of rare disease genes. This development builds upon over two decades of AI expertise and complements QCI Interpret's meticulously curated human-certified content, extending its capabilities to encompass the entire clinical exome.

Key enhancements include:

1. Extended AI-derived references: QCI Interpret now seamlessly integrates AI-derived references for thousands of additional genes within the clinical genome, augmenting the existing QIAGEN-curated content. This combination of human-certified and AI-derived data streamlines the process of prioritizing, assessing, and evaluating clinically significant genetic variants, equipping diagnostic laboratories with comprehensive and dependable information for handling larger gene panels.

2. Enhanced AI-driven phenotype-based ranking: The software's upgraded functionality significantly improves the precision and efficiency of exome sequencing by more accurately identifying gene mutations associated with diseases. Users now have the capability to filter publications exclusively for phenotype-related references, significantly reducing the time required for reviewing literature during variant classification.

3. Improved NGS testing for Oncology: QCI Interpret for Oncology introduces new features, including report revision capabilities, optimized filtering for structural variants, and rapid identification of clinical literature relevant to diseases.

Jonathan Sheldon, Senior Vice President of QIAGEN Digital Insights, emphasized the significance of this expansion, particularly given the decreasing costs associated with whole-exome and whole-genome sequencing. Sheldon stated, "By improving QCI Interpret, we are helping researchers tackle this challenge." With additional AI functionalities, the software now encompasses the entire exome. We amalgamate human-curated and AI-derived content to provide our customers with comprehensive, dependable, and precise data. Our solution stands as the pinnacle of quality and comprehensiveness in the clinical NGS reporting landscape."

QCI Interpret has a storied history of combining QIAGEN's expert curation with efficient AI curation, resulting in dependable interpretation and documentation of genetic variants. With over 3.5 million NGS patient tests analyzed and interpreted globally, QCI Interpret is a widely acknowledged platform that facilitates access to clinical data, bolstering confident decision-making in genetic testing.

This expansion further extends the global reach and adoption of QCI Interpret, with notable instances such as its selection by the National Genome Center of Denmark for variant interpretation in oncology genome sequencing. It plays a pivotal role in supporting cancer patients across Denmark with sequence-based solutions.

 

Source: globenewswire.com

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024